Anatomy hub
Knee: Options and What the Evidence Actually Shows
Osteoarthritis, meniscus injury, and ligament problems dominate knee searches. Here is the standard ladder of care — and where autologous cell approaches enter the conversation.
Anatomy and clinical context
The knee is a weight-bearing hinge with cartilage, menisci, ligaments, and synovium that all age and fail differently. Pain is common; the diagnosis behind it is not always the same.
Most patients work through activity modification, physical therapy, bracing, oral meds, and image-guided injections before considering surgery. Regenerative injectates are often discussed in that middle band — after conservative care, before or instead of arthroplasty in selected cases.
Illustration of the human knee joint
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Activity modification, physical therapy, weight management, bracing, and oral analgesics or anti-inflammatories.
- Step 2
Injections
Corticosteroid, hyaluronic acid, PRP, and orthobiologic injectates including same-day bone marrow or adipose-derived products when a physician recommends them.
- Step 3
Surgery
Arthroscopy for selected mechanical problems; osteotomy or partial/total knee replacement when joint disease is advanced.
Where cell therapy fits
Large controlled trials of same-day, minimally manipulated products in knee OA have often landed at parity with cheaper comparators. That does not mean cells never help — it means dose and product type matter, and honest reading of the literature is part of good care.
- MILES (Mautner, Nature Medicine 2023) compared BMAC, umbilical tissue, and SVF to corticosteroid in knee OA: none beat steroid at one year; MRI scores did not improve.
- Shapiro (AJSM 2017) compared BMAC to saline in contralateral knees — no difference on primary endpoints.
- Culture-expanded products such as Cartistem (Korea) and Stempeucel (India) illustrate pathways where therapeutic dose is engineered — the argument for banking younger cells and expanding later.
Selected citations
MILES
Mautner et al. · Nature Medicine (2023)
n=440 knee OA trial: BMAC, umbilical tissue, and SVF vs corticosteroid — none beat steroid at one year; none moved MRI scores.
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Cartistem
Approved product (Korea) · Regulatory approval (2012)
Culture-expanded allogeneic MSC product approved in Korea with structural signal in cartilage repair settings.
Stempeucel
Approved product (India) · Regulatory approval (2020)
Culture-expanded MSC product approved in India — example of dose-enabled products showing clinical pathway beyond same-day unexpanded injectates.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.